Articles

Podcasts

Videos

Rheumatology

The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.

FDA Approves Secukinumab for Axial Spondyloarthritis

Study drug also recently showed promise in treating psoriatic arthritis.

Secukinumab Reduces Spinal Pain for Axial Spondyloarthritis

The sBLA indication is the fifth for the IL17A inhibitor, which showed reduction of inflammatory signs and symptoms in treated patients at 52 weeks.

FDA Approves Ixekizumab for Non-Radiographic Axial Spondyloarthritis

How therapies are advancing treat-to-target strategies, while the field faces a physician shortage issue.

James Mossell, DO: Meeting Needs in Rheumatology

Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.

Upadacitinib Shows Promise for Ankylosing Spondylitis in SELECT-AXIS 1

Deodhar discusses the results of a study comparing the symptoms and treatment patterns in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.

Atul Deodhar, MD: Treatment Disparities in nr-axSpA and Ankylosing Spondylitis

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.   

PREVENT Trial Data Supports Use of Secukinumab for Spondyloarthritis

A 12-week phase 2 study comparing filgotinib to placebo found the oral, selective JAK1-inhibitor could be an effective treatment for ankylosing spondylitis.

Filgotinib Could Be Effective for Treating Ankylosing Spondylitis

While conferences and annual meetings are often the place clinicians are exposed to new data, there are often niche areas where they seek further guidance or information. Janet Pope, MD, discusses where she would like to see more research dedicated. 

Janet Pope, MD: Rheumatoid Areas in Most Need of Research

The new approval represents the third time the FDA approved the injection treatments for adults.